1. Search Result
Search Result
Results for "

3CL <sup>Pro</sup> inhibition

" in MedChemExpress (MCE) Product Catalog:

5527

Inhibitors & Agonists

13

Screening Libraries

33

Fluorescent Dye

19

Biochemical Assay Reagents

2275

Peptides

2

MCE Kits

30

Inhibitory Antibodies

517

Natural
Products

176

Recombinant Proteins

903

Isotope-Labeled Compounds

39

Antibodies

108

Click Chemistry

850

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108137
    Z-LVG-CHN2
    2 Publications Verification

    Cathepsin HSV SARS-CoV Infection Inflammation/Immunology
    Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC50=190 nM) via inhibition of SARS-COV-2 3CL pro protease [3].
    Z-LVG-CHN2
  • HY-108137A

    Cathepsin HSV SARS-CoV Infection
    Z-L(D-Val)G-CHN2 is the isoform of Z-LVG-CHN2 (HY-108137). Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC50=190 nM) via inhibition of SARS-COV-2 3CL pro protease [3].
    Z-L(D-Val)G-CHN2
  • HY-139311

    SARS-CoV Infection
    YH-53 is a potent 3CL pro inhibitor with Ki values of 6.3 nM, 34.7 nM for SARS-CoV-1 3CL pro and SARS-CoV-2 3CL pro, respectively. YH-53 strongly blocks the SARS-CoV-2 replication. YH-53 is a peptidomimetic compound with a unique benzothiazolyl ketone. YH-53 has the potential for COVID-19 research .
    YH-53
  • HY-162414

    SARS-CoV Infection
    SARS-CoV-2-IN-84 (compound 20) is aSARS-CoV-2 inhibitor that targets the 3CL protease (3CL Pro) of SARS-CoV-2 (IC50: 369.5 nM ) .
    SARS-CoV-2-IN-84
  • HY-133828

    5-HT Receptor SARS-CoV Infection
    Cinanserin (SQ 10643) is a potent and selective 5-HT2 antagonist with Ki values of 41, 3500 nM for 5-HT2, 5-HT1, respectively. Cinanserin also is a SARS-CoV 3CL pro inhibitor with an KD value of 49.4, 18.2 µM for SARS-CoV 3CL pro, HCoV-229E 3CL pro, respectively. Cinanserin reduces systemic burn edema levels [3].
    Cinanserin
  • HY-144062

    SARS-CoV Infection
    INSCoV-614(1B) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
    INSCoV-614(1B)
  • HY-144061

    SARS-CoV Infection
    INSCoV-601I(1) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
    INSCoV-601I(1)
  • HY-144063

    SARS-CoV Infection
    INSCoV-600K(1) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
    INSCoV-600K(1)
  • HY-147020

    NK01-63

    SARS-CoV Infection
    Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. The SARS-CoV-2 3CL protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle .
    Coronastat
  • HY-149655

    SARS-CoV Infection
    D1N8 is a potent SARS-CoV-2 3CL pro inhibitor with an IC50 and CC50 values of 0.44 μM and >20 μM, respectively. D1N8 has the potential for the research of anti-SARS-CoV-2 agents targeting 3CL pro .
    D1N8
  • HY-152005

    SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL pro with an IC50 value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 3CLpro-IN-6
  • HY-163067

    SARS-CoV Infection
    SARS-CoV-2-IN-71 (compound 8h) is a potent inhibitor of SARS-CoV-2. SARS-CoV-2-IN-71 inhibits coronavirus replication at multiple stages. SARS-CoV-2-IN-71 displays anti-coronaviral effect by simultaneously acting on 3CL pro and TMPRSS2 .
    SARS-CoV-2-IN-71
  • HY-157778

    SARS-CoV Infection
    MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 of 8.7 nM .
    MK-7845
  • HY-132306
    CCF0058981
    1 Publications Verification

    CCF981

    SARS-CoV Virus Protease Infection
    CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent SARS-CoV-2 3CL pro (SC2) inhibitor with an IC50 of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CL pro) with an IC50 of 19 nM. CCF0058981 has antiviral efficacy and has the potential for COVID-19 research .
    CCF0058981
  • HY-149656

    SARS-CoV Infection
    D1N52 is a potent SARS-CoV-2 3CL pro inhibitor with an IC50 of 0.53 μM .
    D1N52
  • HY-144833

    SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL pro. 3CL pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .
    SARS-CoV-2 3CLpro-IN-1
  • HY-150691

    SARS-CoV Cancer
    SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC50 value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole .
    SARS 3CLpro-IN-1
  • HY-146998

    SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases .
    SARS-CoV-2 3CLpro-IN-2
  • HY-139683

    SARS-CoV Infection
    Antiviral agent 5 is an intermediate used in antiviral agents targeting 3C and 3CL proteases including SARS-CoV-2 M pro.
    Antiviral agent 5
  • HY-17007
    Saquinavir
    5+ Cited Publications

    Ro 31-8959

    HIV HIV Protease SARS-CoV Infection Cancer
    Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.36 μM.
    Saquinavir
  • HY-100701

    Cathepsin SARS-CoV Virus Protease Infection Cancer
    Dutacatib is inhibitor for SARS-CoV-2 3CL pro and cathepsin K, which exhibits antiviral activity and ameliorates the cancer-induced bone diseases .
    Dutacatib
  • HY-152589

    SARS-CoV Infection
    Antiviral agent 25 (compound 6g) is a new non-peptide analog covalent inhibitor of SARS-CoV-2 3CL pro. Antiviral agent 25 has a strong inhibitory effect on SARS-CoV-2 3CL pro and SARS-CoV-2 PL pro with IC50 values of 0.118 µM, 0.448 µM, respectively. Antiviral agent 25 has antiviral effect on SARS-CoV-2 with an EC50 value of 7.249 µM .
    Antiviral agent 25
  • HY-90001
    Ritonavir
    20+ Cited Publications

    ABT 538; RTV

    HIV Protease HIV SARS-CoV Apoptosis Infection Cancer
    Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.61 μM.
    Ritonavir
  • HY-137048
    PF-00835231
    2 Publications Verification

    SARS-CoV HIV HCV Infection
    PF-00835231 is a CoV-2 cysteine 3C-like protease (3CL pro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CL pro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19. PF-00835231 can inhibit cell infections and also suppress infections in animal models [3].
    PF-00835231
  • HY-N8471

    Parasite SARS-CoV Infection Inflammation/Immunology
    Niazinin is a thiocarbamate glycoside with antileishmanial activities, with an IC50 value of 5.25 μM. Niazinin also shows a binding affinity with the target protein 3CL protease. Niazinin has promising leishmanicidal, anti-inflammatory and anti-pyretic activity .
    Niazinin
  • HY-17430
    Amprenavir
    5+ Cited Publications

    VX-478

    HIV HIV Protease SARS-CoV Infection Cancer
    Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.09 μM.
    Amprenavir
  • HY-151535

    SARS-CoV Infection Inflammation/Immunology
    SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CL pro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL pro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 3CLpro-IN-5
  • HY-17634
    Glecaprevir
    5 Publications Verification

    ABT-493

    HCV HCV Protease SARS-CoV Infection
    Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 4.09 μM .
    Glecaprevir
  • HY-17007R

    HIV HIV Protease SARS-CoV Infection Cancer
    Saquinavir (Standard) is the analytical standard of Saquinavir. This product is intended for research and analytical applications. Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.36 μM.
    Saquinavir (Standard)
  • HY-154965

    SIM0417; SARS-CoV-2-IN-41

    SARS-CoV Infection
    SARS-CoV-2-IN-41 (compound 2) is a potent SARS-CoV-2 3CL pro inhibitor with an IC50 value of 0.022 µM. SARS-CoV-2-IN-41 shows antiviral effect .
    Simnotrelvir
  • HY-18219
    Walrycin B
    1 Publications Verification

    SARS-CoV Bacterial Antibiotic Infection Inflammation/Immunology
    Walrycin B, an analogue of toxoflavin, is a potent SARS-CoV-2 3CL pro inhibitor with an IC50 of 0.26 μM. Walrycin B is a WalR response regulator inhibitor. Walrycin B has potent activity of inhibiting bacteria growth .
    Walrycin B
  • HY-90001R

    ABT 538 (Standard); RTV (Standard)

    HIV Protease HIV SARS-CoV Apoptosis Infection Cancer
    Ritonavir (Standard) is the analytical standard of Ritonavir. This product is intended for research and analytical applications. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.61 μM.
    Ritonavir (Standard)
  • HY-90001S2

    ABT 538-d8; RTV-d8

    Apoptosis HIV Protease SARS-CoV HIV Isotope-Labeled Compounds Infection Cancer
    Ritonavir-d8 is deuterated labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.61 μM.
    Ritonavir-d8
  • HY-14434
    Asunaprevir
    35+ Cited Publications

    BMS-650032

    HCV HCV Protease SARS-CoV Infection
    Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CL pro activity .
    Asunaprevir
  • HY-133862

    Influenza Virus G protein-coupled Bile Acid Receptor 1 Adenosine Receptor Infection
    SCH-202676 is an allosteric modulator of G protein-coupled receptors (GPCRs) and adenosine receptor (AR). SCH-202676 has antiviral activity and inhibits 3CL pro in a time-dependent manner with an IC50 value of 0.655 µM [3] .
    SCH-202676
  • HY-138687
    Nirmatrelvir
    65+ Cited Publications

    PF-07321332

    SARS-CoV Infection Inflammation/Immunology
    Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CL PRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .
    Nirmatrelvir
  • HY-15602
    Ledipasvir
    30+ Cited Publications

    GS-5885

    HCV SARS-CoV Infection
    Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM [3].
    Ledipasvir
  • HY-15602C

    GS-5885 hydrochloride

    HCV SARS-CoV Infection
    Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM [3].
    Ledipasvir hydrochloride
  • HY-110012

    Adenosine Receptor Infection
    SCH-202676 hydrobromide is an allosteric modulator of G protein-coupled receptors (GPCRs) and adenosine receptor (AR). SCH-202676 hydrobromide has antiviral activity and inhibits 3CL pro in a time-dependent manner with an IC50 value of 0.655 μM [3] .
    SCH-202676 hydrobromide
  • HY-D2342

    Fluorescent Dye Infection
    SARS-CoV-2 3CLpro probe-1 (Compound probe 3) is a selective and activity-based probe for the SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro probe-1 can detect endogenously expressed 3CLpro in SARS-CoV-2-infected cells .
    SARS-CoV-2 3CLpro probe-1
  • HY-D0837
    Imidazole
    2 Publications Verification

    Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene

    Ser/Thr Protease Thrombopoietin Receptor Neurological Disease Inflammation/Immunology
    Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease [3].
    Imidazole
  • HY-10300
    Narlaprevir
    4 Publications Verification

    SCH 900518

    HCV HCV Protease SARS-CoV Infection
    Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.3 μM [3].
    Narlaprevir
  • HY-10237
    Boceprevir
    30+ Cited Publications

    EBP 520; SCH 503034

    HCV Protease HCV SARS-CoV Infection
    Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay [3] . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
    Boceprevir
  • HY-12530
    Velpatasvir
    5+ Cited Publications

    GS-5816

    HCV SARS-CoV Infection Inflammation/Immunology Cancer
    Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir
  • HY-B0689

    MK-639 free base; L-735524 free base

    HIV HIV Protease Apoptosis MMP SARS-CoV Inflammation/Immunology Cancer
    Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CL pro inhibitor [3] .
    Indinavir
  • HY-156007

    SARS-CoV Virus Protease Infection
    SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CL pro with an IC50 of 0.03 μM. SARS-CoV-2 3CLpro-IN-21 also inhibits SARS-CoV-13CL pro with an IC50 of 0.12μM .
    SARS-CoV-2 3CLpro-IN-21
  • HY-145276

    SARS-CoV Infection
    SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    SARS-CoV-2-IN-10
  • HY-145277

    SARS-CoV Infection
    SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    SARS-CoV-2-IN-11
  • HY-15148
    Tipranavir
    5+ Cited Publications

    PNU-140690

    HIV Protease HIV SARS-CoV Infection
    Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL pro activity [3].
    Tipranavir
  • HY-B0689A
    Indinavir sulfate
    5+ Cited Publications

    MK-639; L735524

    HIV HIV Protease SARS-CoV Apoptosis MMP Infection Cancer
    Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a SARS-CoV 3CL pro inhibitor [3] .
    Indinavir sulfate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: